RVRC · XBRL financial data
Revium Rx. financial statements, every fiscal year
The same tables from 2 filings, lined up. Matched by XBRL tag: renamed lines keep their history.
How these numbers work
- Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
- Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
- * marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
- 0 means a filing states zero; a dash (—) means no filing states that number.
- “year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
- Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
- Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
- Shares outstanding come from each filing's cover page, as of the date printed there.
- Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.
Income statement
CSVFiscal years (RVRC's year ends in late December)
Balance sheet
CSVFiscal years (RVRC's year ends in late December)
| In thousands of dollars | Dec 31, 2025 |
|---|---|
| Cash and cash equivalents | 1,678 |
| Total current assets | 3,095 |
| Property and equipment, net | 10 |
| Right-of-use asset | 119 |
| Goodwill | 2,575 |
| Total assets | 8,296 |
| Accounts payable | 163 |
| Accrued liabilities | 461 |
| Total current liabilities | 1,369 |
| Lease liability, non-current | 46 |
| Total liabilities | 1,415 |
| Accumulated deficit | (24,962) |
| Total stockholders' equity | 6,881 |
| Total liabilities and equity | 8,296 |
| Common shares outstanding (cover page) thousands of shares | 61,321 |
Cash flows
CSVFiscal years (RVRC's year ends in late December)
| In thousands of dollars | Dec 31, 2025 |
|---|---|
| Net income (loss) | (13,449) |
Compare with peers
SIC 2834 and related industry codes, similar size. Each row is the latest quarter reported.
How peers are chosen
- SIC 2834 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
- Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
- Runway shows only for companies burning cash with under $10B of public float.
- * marks a quarter worked out from the filing totals: for a 10-K, the year less the first three quarters; for a 10-Q, the year-to-date total less the earlier one.
- A cell reading “not reported” means the filings give no figure for that quarter alone.
| Company | Cash ($K) | Revenue, quarter ($K) | Operating cash flow, quarter ($K) | Shares outstanding | Runway | Quarter |
|---|---|---|---|---|---|---|
| Revium Rx. | 842 | not reported | (626)* | 60.7M | 1.3 quarters | 10-QJun 30, 2026 |
| Edesa Biotech | 10,300 | not reported | (3,083)* | 9.6M | 3.3 quarters | 10-QJun 30, 2026 |
| X4 Pharmaceuticals | 195,095 | 2,400 | (20,788)* | 99.1M | 9.4 quarters | 10-QJun 30, 2026 |
| GeoVax Labs | 3,143 | not reported | (3,658)* | 7.4M | 0.9 quarters | 10-QJun 30, 2026 |
| Akari Therapeutics | 7,694 | not reported | (3,109)* | 155.8B | 2.5 quarters | 10-QJun 30, 2026 |
| Earth Science Tech | 631 | 9,026 | 707 | 287.6M | — | 10-QJun 30, 2026 |
| ProPhase Labs | 20 | 1,011 | (78)* | 15.6M | 0.3 quarters | 10-QJun 30, 2026 |
| Pluri | 3,529 | 335* | (4,443)* | 12.3M | 0.8 quarters | 10-KJun 30, 2026 |
| CalciMedica | 18,617 | not reported | (4,620)* | 34.1M | 4.0 quarters | 10-QJun 30, 2026 |
Not investment advice. Not affiliated with the U.S. SEC.